血管内超声指导与造影指导经皮冠状动脉介入治疗无保护左主干病变的比较
OPTIMAL试验为国际多中心、开放标签、随机对照研究,纳入806例无保护左主干冠状动脉疾病患者,1:1随机接受血管内超声指导PCI(401例)或造影指导PCI(405例)。主要终点为最长随访期内任何卒中、任何心肌梗死、任何血运重建或全因死亡的复合终点。中位随访2.9年时,血管内超声指导组135例(33.7%)发生主要终点事件,造影指导组125例(30.9%)发生主要终点事件(HR 1.11,95%CI 0.87–1.42,P=0.40)。死亡、心肌梗死或血运重建发生率及手术相关和总体安全性事件在两组间似乎相似。
要点
- 无保护左主干病变PCI中,血管内超声指导组主要复合终点事件33.7%(135例)vs 造影指导组30.9%(125例),HR 1.11(95%CI 0.87–1.42),P=0.40,无额外获益。
- 主要终点为任何卒中、任何心肌梗死、任何血运重建或全因死亡的复合终点,中位随访2.9年。
- 死亡、心肌梗死或血运重建的发生率在血管内超声指导组与造影指导组间似乎相似。
- 手术相关安全事件和总体安全事件百分比在两组间似乎相似。
- 研究纳入806例无保护左主干病变患者,平均年龄71.4±10.7岁,78.4%为男性,34.7%有糖尿病。
适用人群与场景
- 无保护左主干冠状动脉疾病并接受经皮冠状动脉介入治疗的患者。
- 国际多中心、开放标签、随机对照试验纳入的806例患者,平均年龄71.4±10.7岁,78.4%为男性,34.7%有糖尿病。
研究设计与关键结果
- 研究类型:国际多中心、开放标签、随机对照试验(OPTIMAL,NCT04111770),806例无保护左主干病变患者1:1随机至血管内超声指导PCI(401例)或造影指导PCI(405例)。
- 主要终点:最长随访期内任何卒中、任何心肌梗死、任何血运重建或全因死亡的复合终点;中位随访2.9年时,血管内超声指导组135例(33.7%)vs 造影指导组125例(30.9%)发生主要终点事件,HR 1.11(95%CI 0.87–1.42),P=0.40。
- 死亡、心肌梗死或血运重建的发生率在两组间似乎相似。
- 手术相关安全事件和总体安全事件的百分比在两组间似乎相似。
证据类型、等级与局限
- 证据类型:国际多中心、开放标签、随机对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于无保护左主干冠状动脉疾病患者,血管内超声指导PCI在卒中、心肌梗死、任何血运重建或全因死亡复合终点方面较造影指导PCI无额外获益,作者结论不支持以改善该复合终点为目的常规升级为血管内超声指导。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Percutaneous coronary intervention (PCI) is increasingly used for revascularization of unprotected left main coronary artery disease. Whether intravascular ultrasonographic (IVUS) guidance during PCI results in better clinical outcomes than conventional angiographic guidance alone is uncertain.
METHODS: In an international, multicenter, open-label trial, we randomly assigned patients with unprotected left main coronary artery disease in a 1:1 ratio to undergo either IVUS-guided PCI or angiography-guided PCI. The primary end point was a patient-oriented composite of any stroke, any myocardial infarction, any revascularization, or death from any cause at the longest follow-up.
RESULTS: A total of 806 patients underwent randomization; 401 were assigned to undergo IVUS-guided PCI and 405 to undergo angiography-guided PCI. The mean (±SD) age of the patients was 71.4±10.7 years, 78.4% of the patients were men, and 34.7% had diabetes. At a median follow-up of 2.9 years, a primary end-point event had occurred in 135 patients (33.7%) in the IVUS-guided PCI group and in 125 patients (30.9%) in the angiography-guided PCI group (hazard ratio, 1.11; 95% confidence interval, 0.87 to 1.42; P = 0.40). The incidence of death, myocardial infarction, or revascularization appeared to be similar in the two groups. The percentages of patients with procedure-related and overall safety events also appeared to be similar in the two groups.
CONCLUSIONS: Among patients with unprotected left main coronary artery disease, IVUS-guided PCI showed no additional benefit over angiography-guided PCI with respect to the incidence of stroke, myocardial infarction, any revascularization, or death from any cause at a median follow-up of 2.9 years. (Funded by Philips Image Guided Therapy Devices and Boston Scientific; OPTIMAL ClinicalTrials.gov number, NCT04111770.).
参考来源
- Testa L, De la Torre Hernandez JM, De Maria GL, et al. IVUS-Guided versus Angiography-Guided PCI in Unprotected Left Main Coronary Disease. N Engl J Med. 2026. PMID: 41911017. doi:10.1056/NEJMoa2600440
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。